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Introduction and Rationale
Community-acquired pneumonia (CAP) continues to be a one 
of the leading causes of morbidity and mortality worldwide 
[1-3]. The prevalence of Streptococcus pneumoniae in CAP, 
especially non-bacteremic pneumococcal CAP, is likely 
underestimated due to a lack of sensitive diagnostic assays 
[4]. A traditional etiologic approach to subjects with CAP 
requiring hospitalization includes obtaining blood and/or 
sputum cultures. Although cultures are highly specific, their 
sensitivity is low [5]. Despite difficulty in identifying etiologic 
agents associated with CAP, S. pneumoniae was estimated to 
cause nearly 600,000 cases of pneumonia among United States 
(U.S.) adults >18 years of age in 2004, of which approximately 
50% occurred in subjects aged >65 years and older [6]. 
In 2000, a 7-valent pneumococcal conjugate vaccine (PCV7) 
was introduced into the U.S. infant immunization program. This 
vaccine was replaced in 2010 with a 13-valent pneumococcal 
conjugate vaccine (PCV13). This vaccination program has had 
a well-documented and significant public health impact among 
those vaccinated [1, 7-12], and unvaccinated children and adults 
have benefited from indirect (herd) protection derived from the 
program [13, 14]. However, most of this indirect effect has been 
reported for invasive pneumococcal disease; the impact in non-
invasive pneumonia is not entirely understood. 
One screening method for detecting infection by S. pneumoniae 
is the BinaxNOW® kit provided by Alere™.  This commonly 
used rapid assay tests for the presence of pneumococcal 
C-polysaccharide (C-PS) antigens in the urine using an 
immunochromatographic membrane test kit. The sensitivity 
of this assay is documented by the manufacturer as 86% 
for bacteremic pneumococcal pneumonia [15]. While the 
BinaxNOW® assay detects C-PS antigen, which is present in all 
S. pneumoniae strains; it does not distinguish among different 
pneumococcal serotypes.
More recently, a Luminex technology-based multiplex urinary 
antigen detection (UAD) assay has demonstrated the ability 
to simultaneously detect 13 different S. pneumoniae serotype-
specific capsular polysaccharides in human urine [16]. These 
University of Louisville
Journal of Respiratory Infections
Rationale and Methods of the Study Protocol: Streptococcus 
pneumoniae Serotypes in Adults 18 Years and Older with 
Radiographically-Confirmed Community-Acquired Pneumonia (CAP)
Ronika Alexander1, Paula Peyrani2, Julio Ramirez2, Wesley H. Self3, Carlos Grijalva4, Francis Counselman5, Gregory 
Volturo6, Heidi Kabler7, Luis Ostrosky-Zeichner8, Richard Wunderink9, Robert Sherwin10, Senen Pena Oliva2, Thomas File11, 
Timothy Wiemken12, Sharon Gray1, Michael Pride1, Kimbal D. Ford1, Qin Jiang1, and Raul Isturiz1
Abstract
This study was an active, prospective surveillance study of adults 18 years and older hospitalized with community-acquired pneumonia (CAP) 
due to Streptococcus pneumoniae conducted at 21 hospitals in ten cities across the United States. This report describes the surveillance 
methodology applied between October 7, 2013 and September 30, 2016, including the identification and description of surveillance areas 
and populations at-risk for CAP hospitalization for estimation of incidence rates for selected study sites.
*Correspondence To: Ronika Alexander 
Work: Address: Pfizer Inc. 500 Arcola Road, 5th Floor Bldg D
Collegeville, PA 19426
Work Email: mailto:Ronika.Alexander@pfizer.com
35ULJRI Vol 1, (4) 2017
STUDY PROTOCOL
©2017, The Authors
polysaccharides correspond to the 13 serotypes in PCV13 (1, 
3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). A notable 
advantage of this UAD assay is its ability to combine multiple 
distinct beads, each conjugated to a different serotype-
specific monoclonal antibody, in a single well with the urine 
to be tested. This allows the detection of all 13 polysaccharides 
simultaneously using only a small sample volume. The UAD 
assay has demonstrated greater sensitivity than culture or 
BinaxNOW® urinary antigen detection and excellent specificity 
in a convenience sample obtained from 776 subjects with 
radiographically confirmed CAP [16], and in a separate 
prospective study of adults with radiographically-confirmed 
pneumonia [17]. In a study conducted in 2010, the use of the 
UAD assay helped to demonstrate PCV7 associated serotypes 
were still prevalent among adults aged ≥50 years with CAP, 
representing 26.6% of all S. pneumoniae serotypes detected 
[19]. Nevertheless, the burden of both non-invasive and invasive 
pneumococcal disease in adults with pneumonia after the 
introduction of PCV13 remains unclear.
To provide more contemporary information about the 
proportion of radiographically-confirmed CAP in adults (≥18 
years old) caused by S. pneumoniae, a large epidemiological 
study was undertaken.  Pneumococcal serotypes were identified 
using the serotype-specific UAD assay and standard culture 
methods. Serotype distribution was estimated for the total 
population and incidence was calculated at selected sites. In 
this report we describe the methodology of the study design, 
including the specifics of subject selection and study procedures.
Objectives
The primary objective of this study was to estimate the 
proportion of pneumonia cases caused by PCV13 S. pneumoniae 
serotypes among adults ≥18 years of age hospitalized with 
radiographically-confirmed pneumonia. Secondary objectives 
included: 1. Description of the full distribution of detected S. 
pneumoniae serotypes; 2. Estimation of the incidence rate of 
CAP overall and CAP caused by S. pneumoniae (SP+ CAP) for 
sites where a population denominator could be established; and 
3. Description of the differences in detection of S. pneumoniae 
by culture, BinaxNOW® and UAD assay.
Study Design
This prospective, multicenter, surveillance study was conducted 
at 21 hospitals in 10 geographically dispersed U.S. cities between 
October 7th, 2013 and September 30th 2016. The institutional 
review board (IRB)/independent ethics committee (IEC) at 
each participating site reviewed and approved the protocol and 
informed consent form before any subjects provided consent.
Inclusion criteria
Subjects 18 years of age and older who presented to a study 
hospital were eligible for enrollment if they met the following 
criteria: 1) the presence of 2 or more of the following a) fever 
(oral temperature > 38°C/100.4°F or tympanic temperature 
>38.5°C/ 101.2°F) or hypothermia (<35.5°C) within 24 hours 
of enrollment b) chills or rigors c) pleuritic chest pain d) cough 
e) sputum production f) dyspnea g) tachypnea h) malaise 
i) abnormal auscultatory findings; 2) radiographic finding 
consistent with pneumonia (chest radiograph or chest computed 
tomography scan obtained no more than 72 hours prior to study 
enrollment); and 3) able and willing to provide urine samples 
for diagnostic evaluation.
Exclusion criteria
Subjects were excluded from the study if they:  1) were 
transferred from another inpatient healthcare facility after 
already being hospitalized for 48 hours or more; 2) had a 
diagnosis of hospital acquired pneumonia (ie, developed signs 
and symptoms of pneumonia after being hospitalized for 48 
hours or more); and 3) were previously enrolled in this study 
within the past 30 days. 
Enrollment Sites
This study enrolled subjects from 21 hospitals in 10 US cities 
(Akron, OH, Chicago, IL, Detroit, MI, Louisville, KY, Nashville, 
TN, Norfolk, VA, Houston, TX, Las Vegas, NV, San Diego, CA 
and Worcester, MA) (Table 1). Pneumonia incidence was 
calculated at sites which were able to establish a population 
denominator: Louisville, KY (nine hospitals), Nashville, TN 
(one hospital) and Chicago, IL (one hospital).
Table 1. Details of 21 enrolling hospital centers 
Incidence surveillance sites
Louisville
The surveillance area for Louisville is Jefferson County, located 
in the northwest region of the state of Kentucky. All nine 
hospitals providing adult hospitalization for pneumonia were 
included in this study. The adult census population of Louisville 
was used as the denominator for incidence rate calculations, 
while the numerator was derived from the number of Louisville 
residents hospitalized for CAP. The annual population incidence 
rate per 100,000 adults was estimated for this catchment area. 
Although all eligible cases were identified, approximately 20% 
of patients did not consent to participate in the study (Table 2). 
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Institution Name City State Setting Number of Adult Beds 
Sentara Norfolk  





Sharp Grossmont  
Medical Center 
La Mesa  
(San Diego) CA Community Hospital 532 
Sharp Chula Vista  
Medical Center 
Chula Vista 




(San Diego) CA Community Hospital 397 
Northwestern University 





University of Louisville  





Robley Rex VA  
Medical Center Louisville KY Teaching Hospital 109 
Jewish Hospital Louisville KY Community Hospital 412 
Saint Mary & Elizabeth Hospital Louisville KY Community Hospital 298 
Norton Hospital Louisville KY Community Hospital 859 
Norton Brownsboro Hospital Louisville KY Community Hospital 127 
Norton Audubon Hospital Louisville KY Community Hospital 432 
Norton Suburban Hospital Louisville KY Community Hospital 373 
Baptist Hospital East Louisville KY Community Hospital 468 
UMASS Memorial  
Medical Center Worcester MA Academic Hospital 779 
Detroit Receiving Hospital Detroit MI Academic Urban Medical Center 248 
Sinai-Grace Hospital Detroit MI Academic Urban Medical Center 299 
Sunrise Hospital and  
Medical Center Las Vegas NV Community Hospital 638 
Summa Health System Akron OH Community-based teaching hospital 542 
Vanderbilt University  
Medical Center Nashville TN 
Academic Hospital in 
urban setting 906 
University of Texas  
Medical School at Houston Houston TX 
Not for profit, 
University-affiliated 
tertiary care center 
733 
This 20% of unconsented CAP patients will be factored into the 
numerator for this site. 
The comprehensive management group in Louisville included 
over 60 team members performing functions that spanned 
all aspects of study management. The overall accountability 
remained with the Principal Investigator, however daily 
operations were led by the coordinating center manager. 
Study related activities were stratified into four categories: 1) 
compliance/administration, 2) data science/infrastructure, 3) 
clinical operations and 4) laboratory/biorepository operations.
The compliance and administration group managed budgets, 
payments, invoicing, IRB approvals, issues of informed consent, 
and compliance with all federal, state, local and university study 
conduct requirements.  The data science and infrastructure 
group was responsible for maintaining security of the data 
during collection, transmission, and storage, management 
of data quality monitoring meetings, development and 
implementation of the Data Security Plan, and implementing 
real-time reporting of enrollment across the coordinating 
center. The clinical operations team was responsible for the 
development of Standard Operating Procedures (SOPs) for 
clinical operations, the manual of operations, development 
of data collection forms and training in their use, study team 
management and training, ensuring adequate supply of 
materials needed for daily operations, establishing tools for 
assessment of coordinators as well as testing procedures and 
processes. Laboratory and biorepository operations developed 
the process for specimen collection, analysis, and tracking and 
documented receipt, shipment, and storage of study specimens.
Chicago and Nashville
The surveillance centers for Nashville and Chicago are located 
at Vanderbilt University Medical Center and Northwestern 
Memorial Hospital, respectively. Each represents only one 
of multiple hospitals in the Nashville and Chicago regions, 
respectively.  Both are large urban hospitals serving adult 
general medical and surgical patients. For the Nashville site, 
patients were enrolled from 9 counties around Nashville area 
(Cheatham, Davidson, Dickson, Montgomery, Robertson, 
Rutherford, Sumner, Trousdale, and Williamson). Eight other 
hospitals in the area treat adult pneumonia. Thus, the cases 
enrolled at this site did not represent all cases in this catchment 
area (nine counties); however estimations of incidence 
were performed by applying market share estimation. The 
Tennessee Hospital Discharge Data System (HDDS) database 
was used to determine the percentage (market share) of CAP 
hospitalizations contributed by Vanderbilt University hospital 
among the total hospitals within the nine counties. All hospitals 
in Tennessee are required to report discharge diagnoses for each 
hospitalization, emergency department visit and outpatient 
clinic visit to the HDDS system.
The incidence from the Chicago site was also calculated using the 
market share method.  COMPdata-Illinois Health and Hospital 
Association provided the market share for Northwestern 
Memorial Hospital pneumonia hospitalizations among Cook 
County residents [19]. Approximately 32% of CAP patients did 
not provide consent for enrollment in the study. This will be 
factored into the incidence calculation for this site. 
Table 2. Estimated catchment area denominator and 
market share for incidence calculations
Subjects
Subjects with suspected pneumonia who provided written 
informed consent were screened for inclusion in the study. 
Subjects were actively identified during normal day to day 
procedures at participating centers.  Subject recruitment 
included at a minimum a daily review of the emergency 
department and admission records for potential subjects, as 
well as doctor-to-doctor communication regarding the study. 
Subjects identified outside of normal daily procedures were also 
contacted, evaluated and recruited on the following calendar 
day. 
Sites used for the estimation of incidence employed several 
approaches to ensure complete identification of all patients 
meeting study criteria. In Louisville, the Clinical Research 
Coordinating Center at the University of Louisville Division 
of Infectious Diseases operationalized the project across all 
nine participating hospitals.  Adult patients presenting to 
participating hospitals with the following conditions were 
assessed via electronic medical records (EMR) for inclusion 
in the study: respiratory failure, congestive heart failure, 
aspiration, stroke, urinary tract infection, confusion, and altered 
mental status.  Initial radiographic findings were reviewed for 
patients meeting any of the criteria.  Patients with findings 
consistent with pneumonia were approached for inclusion in the 
study. 
Eligible patients presenting in Nashville were identified 
electronically utilizing the EMR system at Vanderbilt University 
Medical Center (StarPanel®).  The system was programmed to 
alert the study team of chest x-ray and CT findings potentially 
consistent with pneumonia. Research team members stationed 
in the emergency department were then dispatched to further 
evaluate patients for inclusion. In Chicago, individual research 
coordinators screened hospital admission records daily for 
patients meeting inclusion criteria.  Identified patients were 
subsequently contacted for further evaluation for study 
inclusion.  
Study Procedures
Results of chest imaging (X-ray or CT scan) performed per the 
standard of care were recorded. Images obtained within 72 
hours prior to the signing of informed consent could be used in 
addition to those obtained at the time of hospitalization. Upon 
confirmation of eligibility, further information was collected, 
including demographic information, pneumonia severity 
index (PSI) and medical history (including chronic obstructive 
pulmonary disease [COPD], asthma, congestive heart failure 
[CHF], coronary artery disease, chronic kidney disease, diabetes 
and liver disease, immunosuppressive therapy, autoimmune 
disease, HIV/AIDS, solid and hematologic tumors and organ 




*Adjusted for an estimated 32% non-consented rate.  
 **Adjusted for a 20% non-consented rate. 
	
 Chicago* Nashville* Louisville** 
Year 1 date Oct. 2013-Sept. 2014 Nov. 2013-Oct. 2014 June 2014-May 2015 
   Market share ages 18-64 years 4.57% 14.30% 100% 
   Market share ages 65+ 3.63% 7.23% 100% 
Year 2 date Oct. 2014-Sept. 2015 Nov. 2014-Oct. 2015 June 2015-May 2016 
   Market share ages 18-64 years 4.30% 13.39% 100% 
   Market share ages 65+ 3.47% 6.38% 100% 
transplantation).  Self-reported vaccination status was collected 
for influenza (within the previous year) and pneumococcal 
vaccine exposure (within the previous five years). 
Urine was collected via micturation as soon as possible 
following the signing of the informed consent. Urine samples 
were frozen and stored for subsequent UAD and BinaxNOW® 
testing. If a blood culture was not obtained as standard of care, 
it was performed by the study team within 24 hours of study 
enrollment. Available results of blood and respiratory cultures 
(sputum, tracheal aspirate, bronchial washing, pleural fluid, 
etc.), including antibiotic susceptibility testing, were recorded. 
S. pneumoniae isolates obtained from the sites were sent to a 




Subjects had a final diagnosis recorded based on available data, 
including both study and standard of care exams, procedures 
and tests through hospital discharge or hospitalization day 10, 
which ever occurred first. Principal investigators confirmed 
whether the subject had clinical and radiographically confirmed 
pneumonia and recorded the subjects’ vital status. A final 
assessment was conducted to determine subject vital status at 
30 days post-enrollment, either by phone call or follow-up as 
standard of care. 
Urine assays
The BinaxNOW® antigen test is a rapid assay for the qualitative 
detection of S. pneumoniae antigen in the urine of patients 
with pneumonia [2o]. The UAD is a validated limit assay with 
defined positivity cut-off limits and is based on the ability of 
individual serotype-specific monoclonal antibodies to detect the 
polysaccharides of the 13 serotypes covered by PCV13 in urine.  
Statistics
Sample Size Determination
The primary objective of this study was to estimate the 
proportion of adults hospitalized with CAP infected with a 
PCV13 S. pneumoniae serotype. Sample size determination was 
based on the 95% confidence interval around this proportion. 
With a sample size of 216 subjects at each site and an expected 
proportion of 0.10, an approximate 95% confidence interval will 
be ±0.04 at a given site. 
Analyses
The primary study analysis population was comprised of subjects 
meeting all inclusion criteria, with a final diagnosis of CAP, and 
no evidence of pneumococcal vaccination within 30 days prior 
to enrollment. A subject with SP+CAP was defined as a patient 
meeting criteria for CAP and with S. pneumoniae identified by 
UAD, BinaxNOW®, or cultures. The primary endpoint of this 
study was the proportion of subjects with clinically (confirmed 
diagnosis of CAP at final assessment) and radiographically-
confirmed CAP who had any of the S. pneumoniae serotypes 
from the PCV13 vaccine based on the UAD assay or culture. This 
proportion was summarized for all sites with 95% confidence 
interval using the exact method.
The proportion of subjects with PCV13 vaccine type (VT) and 
non-vaccine type (non-VT) S. pneumoniae was summarized by 
site and geographic region in the full analysis population. To 
examine the differences in detection by the different methods, 
the proportion of subjects with detection of S. pneumoniae 
by culture, BinaxNOW®, and UAD assay were summarized 
by method (among patients with tests performed). Serotype 
distribution of S. pneumoniae isolates was described by 
determining the proportion of subjects for each of the S. 
pneumoniae serotypes. Antibiotic resistance rates of S. 
pneumoniae isolates were also determined.
Incidence
For sites with well-defined catchment areas, annual pneumonia 
incidence rates per 100,000 at risk population were estimated. 
All incidence rates were computed separately, as well as 
an annualized rate of the two study years combined. The 
numerators for each of the incidence rate calculations were the 
respective numbers of cases during the designated time periods 
as operationalized in the case definitions; the denominators 
were the corresponding estimated population figures provided 
by the US census bureau. Ninety-five percent confidence 
intervals, based on the Poisson distribution were computed for 
all incidence rates. Incidence rates were also computed for key-
sub-groups (e.g., age and gender).
Discussion
This is the largest surveillance study for S. pneumoniae 
CAP among hospitalized adults in the U.S. with the ability to 
measure non-invasive pneumococcal disease and identify causal 
serotypes.  The results of this prospective study will provide 
epidemiologic information concerning the current burden of 
CAP due to S. pneumoniae, including the current distribution of 
pneumococcal serotypes and their incidence based on population 
surveillance.   Previous analyses of S. pneumoniae incidence [2, 
21] in CAP have been performed in the U.S.; however, they were 
conducted before widespread use of PCV13 in children, and 
before the increasing use of PCV13 among adults seen in recent 
years. Current data on S. pneumoniae serotype distribution in 
CAP are also limited, as few studies have measured both non-
invasive and invasive disease utilizing non-culture methods to 
identify S. pneumoniae in adults. 
Importantly, the population surveillance conducted in the 
Louisville sites provides virtually complete capture of the 
population at risk for CAP in this area, and therefore yields an 
incidence rate representative of 100% of the market share in the 
Louisville area. Market share methodologies for the estimates of 
incidence in Chicago and Nashville hospital sites (~5-15% market 
share at one hospital in each location) may yield incidence rates 
affected by potential differences in patient population at each 
hospital in the catchment area and an inability to capture the 
entire population at risk.
In conclusion, the novel methodology of this study allows for 
a more accurate estimation of the current incidence of PCV13-
isolates among hospitalized patients with CAP in the United 
States via the use of the UAD assay.  In addition, information 
on non-PCV13 serotypes is being gathered via culture methods, 
along with each subject’s PCV13 vaccination status. This 
may have implications both for evaluation of PCV13 vaccine 
effectiveness and non-vaccine serotypes likely to be of increasing 
importance in the near future. 
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